IMTX Quote, Financials, Valuation and Earnings

CureVac NV has a net margin of -974.45% compared to Immatics NV's net margin of -5832.47%. Immatics NV's return on equity of -25.21% beat CureVac NV's return on equity of 20.55%.

Immatics NV has a consensus price target of $18.75, signalling upside risk potential of 57.96%. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 3.97%. Given that Immatics NV has higher upside potential than CureVac NV, analysts believe Immatics NV is more attractive than CureVac NV.

Immatics NV has a beta of 1.361, which suggesting that the stock is 36.134% more volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $6.1M, which are smaller than CureVac NV quarterly revenues of $63.3M. Immatics NV's net income of -$59.1M is lower than CureVac NV's net income of $319.3M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while CureVac NV's PE ratio is 7.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 15.86x versus 14.22x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

Evotec SE has a net margin of -974.45% compared to Immatics NV's net margin of -26.29%. Immatics NV's return on equity of -25.21% beat Evotec SE's return on equity of -17.7%.

Immatics NV has a consensus price target of $18.75, signalling upside risk potential of 57.96%. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 69.18%. Given that Evotec SE has higher upside potential than Immatics NV, analysts believe Evotec SE is more attractive than Immatics NV.

Immatics NV has a beta of 1.361, which suggesting that the stock is 36.134% more volatile than S&P 500. In comparison Evotec SE has a beta of 1.821, suggesting its more volatile than the S&P 500 by 82.079%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $6.1M, which are smaller than Evotec SE quarterly revenues of $191.5M. Immatics NV's net income of -$59.1M is lower than Evotec SE's net income of -$50.3M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 15.86x versus 1.38x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -974.45% compared to Immatics NV's net margin of -51538.49%. Immatics NV's return on equity of -25.21% beat InflaRx NV's return on equity of -82.01%.

Immatics NV has a consensus price target of $18.75, signalling upside risk potential of 57.96%. On the other hand InflaRx NV has an analysts' consensus of $12.78 which suggests that it could grow by 1062.2%. Given that InflaRx NV has higher upside potential than Immatics NV, analysts believe InflaRx NV is more attractive than Immatics NV.

Immatics NV has a beta of 1.361, which suggesting that the stock is 36.134% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $6.1M, which are larger than InflaRx NV quarterly revenues of $27.8K. Immatics NV's net income of -$59.1M is lower than InflaRx NV's net income of -$14.3M. Notably, Immatics NV's price-to-earnings ratio is 42.21x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 15.86x versus 339.88x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Anbio Biotechnology has a net margin of -974.45% compared to Immatics NV's net margin of --. Immatics NV's return on equity of -25.21% beat Anbio Biotechnology's return on equity of --.

Immatics NV has a consensus price target of $18.75, signalling upside risk potential of 57.96%. On the other hand Anbio Biotechnology has an analysts' consensus of -- which suggests that it could fall by --. Given that Immatics NV has higher upside potential than Anbio Biotechnology, analysts believe Immatics NV is more attractive than Anbio Biotechnology.

Immatics NV has a beta of 1.361, which suggesting that the stock is 36.134% more volatile than S&P 500. In comparison Anbio Biotechnology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Immatics NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anbio Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immatics NV pays -- of its earnings as a dividend. Anbio Biotechnology pays out -- of its earnings as a dividend.

Immatics NV quarterly revenues are $6.1M, which are larger than Anbio Biotechnology quarterly revenues of --. Immatics NV's net income of -$59.1M is higher than Anbio Biotechnology's net income of --. Notably, Immatics NV's price-to-earnings ratio is 42.21x while Anbio Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immatics NV is 15.86x versus 195.10x for Anbio Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.